Application of cistanche deserticola extract and echinacoside in preparation of medicine with gastric mucosa protection effect
Through the application of Cistanche extract and echinobacterium glycoside, the problem of poor efficacy of natural products in the prior art in the treatment of gastric ulcers and gastric mucosal injuries was solved, and drugs with significant gastric mucosal protection were developed, which achieved gastric ulcers. and effective treatment of gastric mucosal injury.
Patent Information
- Application Number
- CN202411208855.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2043-05-23
AI Technical Summary
The prior art has insufficient therapeutic effect on the treatment of gastric ulcers and gastric mucosal injuries, and there is a lack of drugs that have significant therapeutic effects on gastric ulcers and gastric mucosal injuries.
Using Cistanche extract, especially total glycans, polysaccharides and oligosaccharides extracted from Cistanche and Cistanche, as well as natural product monomers such as echinobacteria, was developed through pharmacodynamic experiment screening to develop gastric mucosa protection effects. medicine.
It significantly improves the protective effect of the gastric mucosa, prevents and treats gastric ulcers, reduces alcohol-induced liver damage and gastric mucosa damage, and has important clinical significance and commercial value.
Smart Images

Figure CN119074742A_ABST
Abstract
Description
[0001] This application is a divisional application of the patent application with application number 202310585966.5 filed on May 23, 2023. Technical Field
[0002] The invention belongs to the field of medicine, relates to a new use of a Cistanche deserticola extract, and specifically relates to the use of the Cistanche deserticola extract and echinacoside in preparing a medicine with a gastric mucosa protective effect. Background Art
[0003] Gastric ulcer is one of the most common chronic gastrointestinal disorders in the world, with an incidence rate of up to 10%. Gastric ulcer is a multifactorial and multipathway disease with the main clinical manifestations of long-term cyclical and rhythmic upper abdominal pain accompanied by a series of gastrointestinal symptoms such as nausea, vomiting, regurgitation, belching, and heartburn.
[0004] In addition, excessive drinking can also cause gastric mucosal damage and gastric ulcers. The main component of alcohol, ethanol, can dissolve in lipids and enter the stomach wall, causing gastric mucosal damage, increased permeability, gastric mucosal congestion, gastric mucosal erosion and bleeding, etc. In severe cases, it can cause gastric perforation and massive gastrointestinal bleeding, seriously threatening the patient's life safety.
[0005] The treatment of gastric ulcer and gastric mucosal injury is mainly based on drugs, including chemical drugs and traditional Chinese medicine, but the treatment is difficult. Chemical drugs mainly include metronidazole, cimetidine, aluminum sulfate, amoxicillin, omeprazole, etc., while traditional Chinese medicine is mostly compound preparations. Among them, compared with chemical drugs, traditional Chinese medicine compound treatment of gastric ulcer has higher safety. Extracting and separating natural products of traditional Chinese medicine for the treatment of alcoholic gastric injury is an important method for developing stomach protection, anti-gastric ulcer drugs and health products. However, the current efficacy of natural products in the treatment of gastric ulcer and gastric mucosal injury is not significant enough. Therefore, using traditional Chinese medicine as raw materials to develop drugs with significant therapeutic effects on gastric ulcer and gastric mucosal injury has important application value and economic benefits.
[0006] Cistanche deserticola is a perennial parasitic medicinal plant of the genus Cistanche in the family Orobanchaceae. It has extremely high medicinal value and is known as the "desert ginseng". In my country, Cistanche deserticola is mainly distributed in Xinjiang and Inner Mongolia, and is also distributed in Gansu and Ningxia. There are 4 species of Cistanche deserticola in my country, namely C. deserticola YCMa, C. salsa (CAMey.) G. Beck, C. tubulosa (Schenk) R. Wight and C. sinensis G. Beck (Tu Pengfei et al., Modern Chinese Medicine, 2015, 17 (4): 297-301). Among them, C. deserticola and C. tubulosa are officially recognized as the original plants of the Chinese medicine Cistanche deserticola and are included in the "Chinese Pharmacopoeia". Studies have shown that the polysaccharide extract and phenylethanoid glycosides of Cistanche deserticola can improve the recovery of serum and liver indicators in alcohol-induced liver injury model mice, increase the survival of HepG2 cells, and reduce fat microvesicles and necrotic cells in the liver tissue of model animals. It can be seen that the polysaccharide extract and phenylethanoid glycosides of Cistanche deserticola have a significant protective effect on ethanol-induced chronic liver injury. Other studies have shown that the polysaccharide-rich Cistanche deserticola extract can activate the immune system, reduce inflammatory mucosal hyperplasia and intestinal Helicobacter pylori infection in mice, and has the effect of preventing colorectal cancer and intestinal inflammation (see, Hou Lei et al., "Research Progress and Industrialization Status of Cistanche Deserticola", Shandong Agricultural Science, Vol. 52, No. 12, 2020, pp. 133-140).
[0007] Echinacoside (ECH) is a natural compound extracted from Cistanche deserticola, and its properties are white crystalline powder. Echinacoside has many biological effects, such as neuroprotection, liver protection, anti-tumor, anti-apoptosis, anti-aging, immunomodulation and reproductive promotion. It also has the effects of lowering blood sugar, lowering blood lipids, promoting bone formation, and resisting pulmonary hypertension and preventing atherosclerosis. Previously, studies have shown that echinacoside can relieve alcohol-induced oxidative stress and cirrhosis (see Zhi Tao, et al. "Echinacoside ameliorates alcohol-induced oxidative stress and hepaticsteatosis by affecting SREBP1c / FASN pathway viaPPARα", Food and Chemical Toxicology, Vol 148, 2021, 111956). In addition, there are studies reporting that the extract of Cistanche tubulosa rich in echinacoside can alleviate colitis in mice induced by sodium dextran sulfate (see Yamin Jia, et al. "Amelioration of Dextran Sulphate Sodium-Induced Colitis in Mice by Echinacoside-Enriched Extract of Cistanchetubulosa", PHYTOTHERAPY RESEARCH, Vol 28, 2014, 110-119). Total glycosides of Cistanche tubulosa and echinacoside can also be used to prevent and treat alcoholic liver damage accompanied by intestinal damage (see CN113425764A).
[0008] From the above review of the prior art, it can be seen that there is no research report on the protective effect of Cistanche deserticola extract and echinacoside on gastric mucosa. The present invention just fills this technical gap. Summary of the invention
[0009] The purpose of the present invention is to solve the deficiencies of the prior art, to realize the development and utilization of natural products using modern drug research methods, and to provide the use of Cistanche deserticola extract and echinacoside in the preparation of drugs with gastric mucosal protective effects in combination with a large number of pharmacodynamic experimental screenings.
[0010] To achieve the purpose of the present invention, the present invention adopts the following technical solutions:
[0011] In a first aspect, the present invention provides a use of a Cistanche deserticola extract in preparing a medicament having a gastric mucosal protective effect.
[0012] In a first aspect, the present invention provides a use of a Cistanche deserticola extract in the preparation of a medicament for preventing or treating gastric mucosal damage or gastric ulcer.
[0013] As an optional mode, in the above application, the Cistanche deserticola extract is extracted from Cistanche deserticola or Cistanche tubulosa.
[0014] As an optional manner, in the above application, the Cistanche deserticola extract is Cistanche tubulosa total glycosides or Cistanche deserticola total glycosides, Cistanche tubulosa polysaccharides or Cistanche deserticola polysaccharides, Cistanche tubulosa oligosaccharides or Cistanche deserticola oligosaccharides extracted from Cistanche tubulosa or Cistanche deserticola.
[0015] Preferably, the preparation method of the total glycosides of Cistanche deserticola, the polysaccharides of Cistanche deserticola or the oligosaccharides of Cistanche deserticola comprises the following steps:
[0016] The decoction pieces of Cistanche tubulosa or Cistanche deserticola are crushed into coarse powder, and 6-10 times of water are added to heat and reflux for extraction three times, each time for 1.5-3 hours, the filtrates are combined, and the mixture is concentrated under reduced pressure to a relative density of 1.15, and the mixture is measured at 50°C, and 85%-95% ethanol is added until the alcohol content reaches 50-70%, and the mixture is precipitated at low temperature for 10-15 hours, and the mixture is filtered. The precipitate is the total polysaccharide part of Cistanche deserticola; the filtrate is concentrated under reduced pressure to a relative density of 1.15, and the mixture is measured at 50°C, and then purified by macroporous resin, and eluted with water and ethanol of different concentrations in turn, and the water eluate is collected, and the mixture is concentrated under reduced pressure to a thick paste, and the total oligosaccharides of Cistanche deserticola are obtained; the mixture is then eluted with 30-50% ethanol, and the eluate is collected, and the mixture is concentrated under reduced pressure and dried to obtain the total glycosides of Cistanche deserticola.
[0017] More preferably, the preparation method of the total glycosides of Cistanche deserticola, the polysaccharides of Cistanche deserticola or the oligosaccharides of Cistanche deserticola comprises the following steps:
[0018] The decoction pieces of Cistanche tubulosa or Cistanche deserticola are crushed into coarse powder, and 8 times the amount of water is added for heating and reflux extraction for three times, each time for 2 hours, the filtrates are combined, and the mixture is concentrated under reduced pressure to a relative density of 1.15, and measured at 50°C, 95% ethanol is added until the alcohol content reaches 60%, and low-temperature precipitation is performed for 12 hours, and the mixture is filtered. The precipitate is the total polysaccharide part of Cistanche; the filtrate is concentrated under reduced pressure to a relative density of 1.15, and measured at 50°C, and then purified by macroporous resin, eluted with water and ethanol of different concentrations in turn, the water eluate is collected, and the mixture is concentrated under reduced pressure to a thick paste to obtain the total oligosaccharides of Cistanche; and then eluted with 40% ethanol, the eluate is collected, concentrated under reduced pressure, and dried to obtain the total glycosides of Cistanche.
[0019] As an optional mode, in the above application, the Cistanche deserticola extract is a natural product monomer.
[0020] Preferably, the natural product monomer is prepared from total glycosides of Cistanche deserticola.
[0021] Preferably, the natural product monomer is selected from one or more of the following: salidroside, verbascoside, 2'-acetylverbascoside, tubuloside A, echinacoside or isovalascoside.
[0022] Preferably, the method for preparing the natural product monomer comprises the following steps:
[0023] Take the total glycosides of Cistanche deserticola, add 6-10 times of water to dissolve, and perform ODS column chromatography, the eluent is methanol-water, and the gradient elution obtains 16 fractions Fr.I-XVI. Fr.IV is eluted by Sephadex LH-20 column chromatography, the eluent is methanol-water, and 10 main fractions Fr.1-Fr.10 are obtained. Fr.5 is semi-preparatively separated by HPLC, the eluent is methanol-water, and the compounds echinacoside and tubuloside A are obtained. Fr.VII is eluted by Sephadex LH-20 column chromatography, the eluent is methanol-water, and 12 main fractions Fr.1-Fr.12 are obtained. Fr.8 is preparatively separated by HPLC, the eluent is water-methanol-acetonitrile, and the compounds verbascoside and 2'-acetyl verbascoside are obtained; Fr.10 is preparatively separated by HPLC, the eluent is methanol-water, and the compound iso-verbascoside is obtained. Fr.VIII was eluted by Sephadex LH-20 column chromatography with methanol-water as the eluent to obtain 8 main fractions Fr.1-Fr.8. Fr.3 was subjected to silica gel PTLC, silica gel H, and chloroform-methanol as the developing solvent to obtain the compound salidroside.
[0024] More preferably, the method for preparing the natural product monomer comprises the following steps:
[0025] Take the total glycosides of Cistanche deserticola, add 8 times the amount of water to dissolve, and 16 fractions (Fr.I-XVI) are obtained by gradient elution through ODS column chromatography (100-120 mesh, methanol-water, 25:75-75:25). Fr.IV is eluted through Sephadex LH-20 column chromatography (methanol-water, 50:50) to obtain 10 main fractions Fr.1-Fr.10, and Fr.5 is semi-preparatively separated by HPLC (methanol-water, 30:70) to obtain compounds echinacoside and tubuloside A. Fr.VII was eluted by Sephadex LH-20 column chromatography (methanol-water, 50:50) to obtain 12 main fractions Fr.1-Fr.12, Fr.8 was separated by HPLC (water-methanol-acetonitrile, 62:29:9) to obtain the compounds verbascoside and 2'-acetyl verbascoside; Fr.10 was separated by HPLC (methanol-water, 40:60) to obtain the compound isoverbascoside. Fr.VIII was eluted by Sephadex LH-20 column chromatography (methanol-water, 50:50) to obtain 8 main fractions Fr.1-Fr.8, and Fr.3 was separated by silica gel PTLC (silica gel H, chloroform-methanol, 3:1) to obtain the compound salidroside.
[0026] More preferably, the natural product monomer is echinacoside.
[0027] As an optional method, in the above application, echinacoside dose-dependently reduces the LDH release rate, inhibits bile acid-induced autophagy overactivation, and dose-dependently significantly downregulates the content of IL-6, IL-1β, and TNFα.
[0028] As an optional mode, in the above application, the medicine only contains the Cistanche deserticola extract as an active ingredient, and also contains a pharmaceutically acceptable carrier.
[0029] As an optional mode, in the above application, the dosage form of the drug is an oral dosage form.
[0030] As an optional mode, in the above application, the oral dosage form is a capsule, a tablet, a granule or an oral liquid.
[0031] Compared with the prior art, the present invention has the following beneficial effects:
[0032] The present invention combines my country's advantages in natural product research and screens out new uses of Cistanche deserticola extract and various natural product monomers including echinacoside in gastric mucosal protection and prevention and treatment of gastric mucosal damage and gastric ulcer. The present invention has the prospect of being developed into a drug for treating related indications and has important clinical significance and commercial value. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1:Activity of each extract component in TCA-induced GES-1 cell injury model. The difference between the two groups was analyzed by t-test, and the data are expressed as Mean±SEM, n=6. Compared with the normal control group, ## P<0.01; compared with the model group, *P<0.05, **P<0.01.
[0034] Figure 2 :Activity of monomer components in TCA-induced GES-1 cell injury model. The difference between the two groups was analyzed by t-test, and the data are expressed as Mean±SEM, n=6. Compared with the normal control group, ## P<0.01; compared with the model group, *P<0.05, **P<0.01, ***P<0.001.
[0035] Figure 3 :In vitro screening of the activity of echinacoside in improving gastric mucosal injury. Among them, A is the effect of ECH on the survival rate of GES-1 cells induced by ethanol; B is the effect of ECH on the survival rate of GES-1 cells induced by bile acid; C is the effect of ECH on the survival rate of cells induced by acetylsalicylic acid. ECH: echinacoside. The differences between the two groups were analyzed by t-test, and the data were expressed as Mean±SEM, n=6. Compared with the normal control group, ## P<0.01; compared with the model group, *P<0.05, **P<0.01.
[0036] Figure 4 :Effect of echinacoside on LDH release rate in bile acid-induced GES-1 cell injury model. ECH: echinacoside. The difference between the two groups was analyzed by t-test, and the data were expressed as Mean±SEM, n=6. Compared with the normal control group, ## P<0.01; *P<0.05 compared with the model group.
[0037] Figure 5 : Effects of echinacoside on bile acid-induced autophagy in GES-1 cells.
[0038] Figure 6 :Effects of echinacoside on the gross appearance of gastric tissues of mice in each group. CG: normal control group, SG: positive control sucralfate, ECH 25: 25 mg / kg echinacoside, ECH 50: 50 mg / kg echinacoside. The red arrow indicates the site of gastric mucosal bleeding.
[0039] Figure 7:Effects of echinacoside on the pathological morphology of gastric tissue in each group of mice. CG: normal control group, SG: positive control sucralfate, ECH 25: 25 mg / kg echinacoside, ECH 50: 50 mg / kg echinacoside. The black arrows indicate the necrosis and disorder of gastric mucosal cells. H&E staining results (×200), scale bar = 50 μm.
[0040] Figure 8 : Effects of echinacoside on the levels of plasma IL-1β, IL-6, and TNFα in ICR mice in each group. Among them, A is the level of plasma IL-6 in ICR mice; B is the level of plasma IL-1β in ICR mice; C is the level of plasma TNFα in ICR mice. CG: normal group; MG: model group; SG: positive drug sucralfate group; ECH 25: 25 mg / kg echinacoside, ECH 50: 50 mg / kg echinacoside. The t-test was used to analyze the differences between the two groups, and the data are expressed as Mean±SEM, n=7. Compared with the CG group, # P<0.05, ## P<0.01; compared with the MG group, *P<0.05, **P<0.01. DETAILED DESCRIPTION
[0041] The present invention will be further described with reference to specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the scope of the present invention.
[0042] The pharmaceutically acceptable carrier of the present invention refers to a conventional drug carrier in the field of pharmaceutical preparations, selected from one or more of fillers, binders, disintegrants, lubricants, suspending agents, wetting agents, pigments, flavoring agents, solvents, and surfactants.
[0043] The filler of the present invention includes but is not limited to starch, microcrystalline cellulose, sucrose, dextrin, lactose, powdered sugar, glucose, etc.; the lubricant includes but is not limited to magnesium stearate, stearic acid, sodium chloride, sodium oleate, sodium lauryl sulfate, poloxamer, etc.; the binder includes but is not limited to water, ethanol, starch slurry, syrup, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, sodium alginate, polyvinyl pyrrolidone, etc.; the disintegrant includes but is not limited to starch effervescent mixture, i.e. sodium bicarbonate and citric acid, tartaric acid, low-substituted hydroxypropyl cellulose, etc.; the suspending agent includes but is not limited to polysaccharides such as acacia gum, agar, alginic acid, cellulose ether and carboxymethyl chitosan, etc.; the solvent includes but is not limited to water, a balanced salt solution, etc.
[0044] The drug can be made into various solid oral preparations, liquid oral preparations, etc. Pharmaceutically acceptable oral solid preparations include: ordinary tablets, dispersible tablets, enteric-coated tablets, granules, capsules, dripping pills, powders, etc., and oral liquid preparations include oral liquids, emulsions, etc. The above-mentioned various dosage forms can be prepared according to conventional processes in the field of pharmaceutical preparations.
[0045] The Cistanche deserticola extract and various natural product monomers including echinacoside used in the present invention can be extracted and separated from Cistanche deserticola by the extraction and separation method described in the present invention or other biological extraction methods reported in the literature, or can be purchased from commercial products.
[0046] In the medical uses described above, the administration time, number of administrations and frequency of administration of Cistanche deserticola extract and various natural product monomers including echinacoside need to be determined according to the specific diagnosis results of the disease, which is within the technical scope mastered by technicians in this field.
[0047] In order to better understand the essence of the present invention, the pharmacodynamics experiments and their results are used in the following specific implementation methods to further illustrate the new uses of Cistanche deserticola extract and echinacoside in the pharmaceutical field.
[0048] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0049] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.
[0050] Unless otherwise specified, all percentages and parts in the present invention are percentages and parts by weight.
[0051] Example 1: Extraction method of total glycosides, polysaccharides and oligosaccharides of Cistanche deserticola 1. Preparation of extracts from various parts of Cistanche tubulosa or Cistanche deserticola (only an exemplary method, and can also be obtained by other means):
[0052] The decoction pieces of Cistanche tubulosa or Cistanche deserticola were crushed into coarse powder, and 8 times the amount of water was added for heating and reflux extraction for three times, each time for 2 hours, the filtrates were combined, and the relative density was concentrated under reduced pressure to 1.15 (measured at 50°C), 95% ethanol was added until the alcohol content reached 60%, low-temperature precipitation was performed for 12 hours, and the precipitate was filtered. The precipitate was the total polysaccharide part of Cistanche; the filtrate was concentrated under reduced pressure to a relative density of 1.15 (measured at 50°C), and then purified by macroporous resin, eluted with water and different concentrations of ethanol in turn, the water eluate was collected, and the total oligosaccharides of Cistanche were obtained; and then eluted with 40% ethanol, the eluate was collected, concentrated under reduced pressure, and dried to obtain the total glycosides of Cistanche.
[0053] 2. Preparation of monomer compounds of Cistanche tubulosa or Cistanche deserticola (only an exemplary method, and can also be obtained by other means):
[0054] Take the total glycosides of Cistanche deserticola, add 8 times the amount of water to dissolve, and 16 fractions (Fr.I-XVI) are obtained by gradient elution through ODS column chromatography (100-120 mesh, methanol-water, 25:75-75:25). Fr.IV is eluted through Sephadex LH-20 column chromatography (methanol-water, 50:50) to obtain 10 main fractions Fr.1-Fr.10, and Fr.5 is semi-preparatively separated by HPLC (methanol-water, 30:70) to obtain compounds echinacoside and tubuloside A. Fr.VII was eluted by Sephadex LH-20 column chromatography (methanol-water, 50:50) to obtain 12 main fractions Fr.1-Fr.12, Fr.8 was separated by HPLC (water-methanol-acetonitrile, 62:29:9) to obtain the compounds verbascoside and 2'-acetyl verbascoside; Fr.10 was separated by HPLC (methanol-water, 40:60) to obtain the compound isoverbascoside. Fr.VIII was eluted by Sephadex LH-20 column chromatography (methanol-water, 50:50) to obtain 8 main fractions Fr.1-Fr.8, and Fr.3 was separated by silica gel PTLC (silica gel H, chloroform-methanol, 3:1) to obtain the compound salidroside.
[0055] Example 2: Screening of the pharmacodynamic activity of Cistanche deserticola extracts on the GES-1 cell injury model induced by taurocholic acid
[0056] The gastric mucosal injury model was established using human gastric epithelial cell line GES-1 cells induced by taurocholic acid (TCA), and the gastric mucosal protective activity of each extract and its main monomer of Cistanche deserticola (abbreviated as Cistanche tubulosa (abbreviated as Tubulosa) was evaluated. The results of previous experiments showed that the IC50 of TCA for GES-1 cell injury was 1.47mM, so this study used 1.5mM TCA as the modeling dose for cell injury. The activity of each extract on the TCA-induced GES-1 cell injury model was evaluated at concentrations of 1, 5, and 10μg / mL.
[0057] The experimental results showed that the cell survival rate in the model group was significantly lower than that in the control group (P < 0.01); and compared with the model group, the cell activity of total glycosides of flos tubulosa, flos tubulosa polysaccharides, and flos tubulosa oligosaccharides was significantly increased at a concentration of 10 μg / mL (P < 0.05), indicating that total glycosides of flos tubulosa and flos tubulosa polysaccharides have significant gastric mucosal protective activity. The cell activity of total glycosides of desert, desert oligosaccharides, and desert polysaccharides was significantly increased at a concentration of 10 μg / mL (P < 0.05), indicating that total glycosides of desert, desert oligosaccharides, and desert polysaccharides have significant gastric mucosal protective activity ( Figure 1 ).
[0058] Example 3: Screening of the pharmacodynamic activity of Cistanche deserticola monomer components on the GES-1 cell injury model induced by taurocholic acid
[0059] The activity screening of the main monomers of Cistanche deserticola was evaluated at concentrations of 1, 5, and 10 μM in the TCA-induced GES-1 cell injury model. The results showed that the cell survival rate in the model group was significantly reduced compared with the control group (P < 0.01); compared with the model group, salidroside and verbascoside could significantly increase cell viability at concentrations of 1, 5, and 10 μM, and were dose-dependent. The increase rate of cell viability was the highest at 10 μM (P < 0.01), indicating that salidroside and verbascoside can protect gastric mucosal cells in a dose-dependent manner. 2'-acetyl verbascoside, echinacoside, and isoverbascoside all significantly increased cell viability at 10 μM, indicating that 2'-acetyl verbascoside, echinacoside, and isoverbascoside have significant gastric mucosal protective activity. Tubuloside A at a concentration of 10 μM can significantly increase cell viability (P < 0.05), indicating that Tubuloside A has significant gastric mucosal protective activity ( Figure 2 ).
[0060] Example 4: Pharmacodynamic activity of echinacoside on different GES-1 cell injury models
[0061] Since the characteristic component of Cistanche deserticola, echinacoside, has the most significant pharmacological activity, this study once again used three in vitro GES-1 cell injury models to evaluate the in vitro gastric mucosal protective pharmacological activity of echinacoside.
[0062] In the 8% ethanol-induced cell injury model, echinacoside at three concentrations of 1, 5, and 10 μM can significantly increase the survival rate of ethanol-damaged cells in a dose-dependent manner (P < 0.01), among which 10 μM echinacoside has the best efficacy. In the 1.5 mM bile acid (BA)-induced GES-1 cell injury model, echinacoside at three concentrations of 1, 5, and 10 μM can also significantly increase the survival rate of bile acid-induced GES-1 cell injury. In the 5 mM acetylsalicylic acid-induced GES-1 cell injury model, echinacoside has significant gastric mucosal cell protective activity at a concentration of 10 μM (P < 0.05). In three different gastric mucosal cell injury models, echinacoside showed good pharmacodynamic activity, laying the foundation for further mechanism exploration and in vitro efficacy verification of this study ( Figure 3 ).
[0063] Example 5: Effect of echinacoside on LDH release rate in bile acid-induced GES-1 cell injury model
[0064] Cell damage will release a large amount of lactate dehydrogenase, so detecting the LDH release rate can evaluate the cytoprotective effect of echinacoside.
[0065] The results showed that bile acid treatment significantly increased the intracellular LDH release rate (P < 0.01), while echinacea glycoside treatment reduced the LDH release rate in a dose-dependent manner (P < 0.05), indicating that echinacea glycoside has a certain cytoprotective effect ( Figure 4 ).
[0066] Example 6: Effect of echinacoside on bile acid-induced autophagy in GES-1 cells
[0067] Cell autophagy is a common stress mechanism of cell damage and the pathological basis of many digestive system diseases. Autophagy is a programmed self-catabolism regulation process. When the cell autophagy process is activated, the cell fragments, damaged organelles and abnormal proteins to be decomposed will be wrapped to form vesicles, which will gradually mature and acidify during cytoplasmic transport, combine with lysosomes to form autophagic lysosomes, and finally be digested, degraded and reused. Acridine orange dye can penetrate into autophagic lysosomes, showing red-yellow fluorescence under a fluorescence microscope, thereby reflecting the level of autophagy in cells.
[0068] In order to explore the effect of echinacoside on the level of autophagy induced by bile acid in GES-1 cells, acridine orange staining was used for analysis. The results showed that the red and green fluorescence levels in the cells were enhanced after bile acid treatment, indicating that cell autophagy was significantly activated. After echinacoside treatment, the red and green fluorescence levels improved, indicating that echinacoside inhibited the excessive activation of autophagy induced by bile acid, and the gastric protective effect of echinacoside was related to the regulation of cell autophagy ( Figure 5 ).
[0069] Example 7: Effects of echinacoside on the gross appearance of gastric tissues in each group of mice
[0070] Healthy male SPF ICR mice, weighing 20-25g, were housed in a barrier environment and fed with normal feed for 1 week, and then randomly divided into 5 groups (10 mice in each group), including normal control group (Control group, CG), model group (Model group, MG), positive drug sucralfate group (Sucralfate-treated group, SG), ECH 25 group (25mg / kg dose of ECH-treated group, ECH 25), and ECH 50 group (50mg / kg dose of ECH-treated group, ECH50). Except for the CG group, the mice in the other groups were gavaged with reflux fluid (2.5% TCA, 1.5% trypsin, 0.25% lecithin) to establish the bile reflux gastritis model, twice a day, at a dose of 15mL / kg. Three days after mice were gavaged with reflux fluid, each group began drug treatment, and the drug treatment lasted for 2 weeks. Six hours after gavage of reflux fluid every day, the ECH group was gavaged with different doses of ECH 25 mg / kg and 50 mg / kg, and the dose of the positive drug sucralfate group was 120 mg / kg.
[0071] When bile reflux causes gastric damage, symptoms of chronic gastritis or gastric ulcer can be seen under gastroscopy, such as uneven color of the gastric mucosa, congestion and brittleness, bleeding spots or ulcer spots, and the presence of green or yellow bile-like fluid in the gastric mucus.
[0072] When the animals were sampled 2 weeks after administration, the gastric mucosa of the mice was photographed and observed in general, which could be used to preliminarily determine the degree of gastric mucosal damage. Figure 6 As shown in the figure, the gastric mucosa of mice in the normal group was intact and ruddy, with normal wrinkles and no redness or swelling, and no ulcers or bleeding spots on the surface. In the model group, obvious bleeding spots appeared on the gastric mucosa, the gastric mucosa was red and swollen, and the wrinkles disappeared. The bleeding spots and redness of the gastric mucosa in the ECH high-dose group and the positive drug sucralfate group were improved.
[0073] Example 8: Effects of echinacoside on gastric tissue pathological morphology of mice in each group
[0074] The animal experiment method is as shown in Example 8. The pathological morphology of gastric tissue sections of mice with bile reflux gastric mucosal injury model was observed by H&E staining, and the pathological morphology of gastric mucosal epithelial cells in each group was observed under a microscope. Figure 7 As shown in the figure, the gastric mucosal structure of the CG group was intact, the epithelial cells were single columnar, and arranged neatly, with almost no defects or shedding. Compared with the CG group, the gastric mucosal epithelial cells in the MG group were shedding and defective, and the intrinsic glands were arranged in disorder, which are similar to the characteristics observed in patients with bile reflux gastritis. After ECH treatment, the above changes were significantly milder than those in the model group, the gastric mucosal structure was basically intact, and the gastric mucosal epithelial cells were arranged relatively neatly and regularly, indicating that ECH treatment can significantly reduce the pathological damage of gastric tissue.
[0075] Example 9: Effects of echinacoside on plasma IL-1β, IL-6, and TNFα levels in mice of each group
[0076] The animal experiment method is shown in Example 7. The gastric mucosa is attacked by irritants such as bile, and the defense factors are damaged, leading to chronic inflammation of the gastric mucosa and tissue damage. IL-1β, IL-6, and TNFα are all markers of inflammatory response. In order to further study the role of ECH in bile reflux gastritis, the levels of inflammatory factors IL-6, IL-1β, and TNFα in plasma were detected.
[0077] like Figure 8 As shown in the data, after 2 weeks of bile reflux, the above three inflammatory factors were significantly upregulated (P < 0.01), while ECH significantly downregulated the levels of IL-6, IL-1β, and TNFα in a dose-dependent manner.
[0078] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. The use of Cistanche deserticola extract in the preparation of a drug having a gastric mucosal protective effect, characterized in that: The Cistanche deserticola extract is a natural product monomer, which is selected from one or more of the following: salidroside, verbascoside, 2'-acetyl verbascoside, tubuloside A, echinacoside or isovalascoside, and is prepared from the total glycosides of Cistanche deserticola.
2. Use of Cistanche deserticola extract in the preparation of a medicament for preventing or treating gastric mucosal damage or gastric ulcer, characterized in that: The Cistanche deserticola extract is a natural product monomer, which is selected from one or more of the following: salidroside, verbascoside, 2'-acetyl verbascoside, tubuloside A, echinacoside or isovalascoside, and is prepared from the total glycosides of Cistanche deserticola.
3. The use according to claim 1 or claim 2, characterized in that: The method for preparing the natural product monomer comprises the following steps: Take the total glycosides of Cistanche deserticola, add 6-10 times the amount of water to dissolve, and chromatograph by ODS column with methanol-water as the eluent to obtain 16 fractions Fr.I-XVI by gradient elution. Fr.IV is eluted by Sephadex LH-20 column chromatography with methanol-water as the eluent to obtain 10 main fractions Fr.1-Fr.
10. Fr.5 is semi-preparatively separated by HPLC with methanol-water as the eluent to obtain compounds echinacoside and tubuloside A. Fr.VII is eluted by Sephadex LH-20 column chromatography with methanol-water as the eluent to obtain compounds echinacoside and tubuloside A. LH-20 column chromatography was used for elution with methanol-water as the eluent to obtain 12 main fractions Fr.1-Fr.
12. Fr.8 was prepared and separated by HPLC with water-methanol-acetonitrile as the eluent to obtain compounds verbascoside and 2'-acetylverascoside. Fr.10 was prepared and separated by HPLC with methanol-water as the eluent to obtain compound isoverascoside. Fr.VIII was eluted by Sephadex LH-20 column chromatography with methanol-water as the eluent to obtain 8 main fractions Fr.1-Fr.
8. Fr.3 was separated by silica gel PTLC with silica gel H and chloroform-methanol as the developing agent to obtain compound salidroside.
4. The use according to claim 1 or claim 2, characterized in that: The natural product monomer is echinacoside.
5. The use according to claim 4, characterized in that: Echinacoside dose-dependently reduced the LDH release rate, inhibited bile acid-induced autophagy overactivation, and dose-dependently downregulated the levels of IL-6, IL-1β, and TNFα.
6. The use according to any one of claims 1 to 5, characterized in that: The medicine only contains the Cistanche deserticola extract as an active ingredient and also contains a pharmaceutically acceptable carrier.
7. The use according to claim 6, characterized in that: The dosage form of the drug is an oral dosage form.
8. The use according to claim 7, characterized in that: The oral dosage form is capsule, tablet, granule or oral liquid.
Citation Information
Patent Citations
Application of herba cistanche based phenylethanoid glycosides to anti-depression
CN109078049A
Medicine for treating atrophic gastritis and preparation method of medicine
CN111166850A
Application of cistanche total glycosides and echinacoside in preparation of medicines for preventing and treating alcoholic liver injury with intestinal injury
CN113425764A
Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
US20090191288A1
